FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140288362> ?p ?o ?g. }

• W2140288362 endingPage "602" @default.
• W2140288362 startingPage "602" @default.
• W2140288362 abstract "OBJECTIVE The purpose of this research was to investigate the anti-angiogenic inhibitory effect of KR-31831, a newly developed anti-angiogenic agent, on an in vivo human ovarian carcinoma model using dynamic contrast-enhanced (DCE) MRI. MATERIALS AND METHODS Xenografted ovarian tumors were established by subcutaneous injection of SKOV3 cells into mice. The mice were treated daily with KR-31831 at 50 mg/kg for 21 days. Tumor tissues were excised corresponding to the DCE-MRI sections for evaluation of MVD with CD31 immunohistochemistry. All in vivo MRIs were performed on a 7.0 Tesla micro-MRI System. DCE-MRI was acquired prior to initiating treatment with KR-31831 and again on days 3 and 21 after treatment. The permeability parameters (K(trans), v(e), and v(p)) were estimated using a pharmacokinetic model. RESULTS Qualitatively, the K(trans) parametric mapping showed different changes before and after treatment with KR-31831 in the treatment group. For quantification of this change, the median of K(trans) values were compared before and after treatments in the control and KR-31831-treated groups. A non-parametric statistical test (Wilcoxon signed-rank test) showed decreasing K(trans) values on day 21 compared to days 0 and 3 in the KR-31831-treated group (p < 0.05), whereas there was no significant difference in the control group (p = 0.84). CONCLUSION Our results suggest that DCE-MRI can be a useful tool by which to evaluate the anti-angiogenic effect of KR-31831 on a xenografted human ovarian carcinoma model." @default.
• W2140288362 created "2016-06-24" @default.
• W2140288362 creator A5000063022 @default.
• W2140288362 creator A5007533948 @default.
• W2140288362 creator A5012756261 @default.
• W2140288362 creator A5015480620 @default.
• W2140288362 creator A5024229749 @default.
• W2140288362 creator A5038609461 @default.
• W2140288362 creator A5049872669 @default.
• W2140288362 creator A5085174655 @default.
• W2140288362 date "2011-01-01" @default.
• W2140288362 modified "2023-10-07" @default.
• W2140288362 title "Evaluation of Antiangiogenic Effects of a New Synthetic Candidate Drug KR-31831 on Xenografted Ovarian Carcinoma Using Dynamic Contrast Enhanced MRI" @default.
• W2140288362 cites W1489361317 @default.
• W2140288362 cites W1542216227 @default.
• W2140288362 cites W1579297325 @default.
• W2140288362 cites W1807482481 @default.
• W2140288362 cites W1965728888 @default.
• W2140288362 cites W1977662918 @default.
• W2140288362 cites W2000176833 @default.
• W2140288362 cites W2019190989 @default.
• W2140288362 cites W2023740387 @default.
• W2140288362 cites W2036913456 @default.
• W2140288362 cites W2042098439 @default.
• W2140288362 cites W2044708294 @default.
• W2140288362 cites W2049827480 @default.
• W2140288362 cites W2052013170 @default.
• W2140288362 cites W2056410635 @default.
• W2140288362 cites W2067293021 @default.
• W2140288362 cites W2070580351 @default.
• W2140288362 cites W2072446438 @default.
• W2140288362 cites W2075880681 @default.
• W2140288362 cites W2100855465 @default.
• W2140288362 cites W2103634327 @default.
• W2140288362 cites W2108610949 @default.
• W2140288362 cites W2112957932 @default.
• W2140288362 cites W2117140276 @default.
• W2140288362 cites W2132057620 @default.
• W2140288362 cites W2158743409 @default.
• W2140288362 cites W4247664461 @default.
• W2140288362 doi "https://doi.org/10.3348/kjr.2011.12.5.602" @default.
• W2140288362 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3168802" @default.
• W2140288362 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21927562" @default.
• W2140288362 hasPublicationYear "2011" @default.
• W2140288362 type Work @default.
• W2140288362 sameAs 2140288362 @default.
• W2140288362 citedByCount "12" @default.
• W2140288362 countsByYear W21402883622012 @default.
• W2140288362 countsByYear W21402883622013 @default.
• W2140288362 countsByYear W21402883622015 @default.
• W2140288362 countsByYear W21402883622016 @default.
• W2140288362 countsByYear W21402883622017 @default.
• W2140288362 countsByYear W21402883622018 @default.
• W2140288362 countsByYear W21402883622019 @default.
• W2140288362 countsByYear W21402883622020 @default.
• W2140288362 countsByYear W21402883622022 @default.
• W2140288362 crossrefType "journal-article" @default.
• W2140288362 hasAuthorship W2140288362A5000063022 @default.
• W2140288362 hasAuthorship W2140288362A5007533948 @default.
• W2140288362 hasAuthorship W2140288362A5012756261 @default.
• W2140288362 hasAuthorship W2140288362A5015480620 @default.
• W2140288362 hasAuthorship W2140288362A5024229749 @default.
• W2140288362 hasAuthorship W2140288362A5038609461 @default.
• W2140288362 hasAuthorship W2140288362A5049872669 @default.
• W2140288362 hasAuthorship W2140288362A5085174655 @default.
• W2140288362 hasBestOaLocation W21402883621 @default.
• W2140288362 hasConcept C121608353 @default.
• W2140288362 hasConcept C126322002 @default.
• W2140288362 hasConcept C126838900 @default.
• W2140288362 hasConcept C143409427 @default.
• W2140288362 hasConcept C154945302 @default.
• W2140288362 hasConcept C2776502983 @default.
• W2140288362 hasConcept C2780427987 @default.
• W2140288362 hasConcept C2989005 @default.
• W2140288362 hasConcept C2994142346 @default.
• W2140288362 hasConcept C3019054536 @default.
• W2140288362 hasConcept C41008148 @default.
• W2140288362 hasConcept C41727105 @default.
• W2140288362 hasConcept C71924100 @default.
• W2140288362 hasConceptScore W2140288362C121608353 @default.
• W2140288362 hasConceptScore W2140288362C126322002 @default.
• W2140288362 hasConceptScore W2140288362C126838900 @default.
• W2140288362 hasConceptScore W2140288362C143409427 @default.
• W2140288362 hasConceptScore W2140288362C154945302 @default.
• W2140288362 hasConceptScore W2140288362C2776502983 @default.
• W2140288362 hasConceptScore W2140288362C2780427987 @default.
• W2140288362 hasConceptScore W2140288362C2989005 @default.
• W2140288362 hasConceptScore W2140288362C2994142346 @default.
• W2140288362 hasConceptScore W2140288362C3019054536 @default.
• W2140288362 hasConceptScore W2140288362C41008148 @default.
• W2140288362 hasConceptScore W2140288362C41727105 @default.
• W2140288362 hasConceptScore W2140288362C71924100 @default.
• W2140288362 hasIssue "5" @default.
• W2140288362 hasLocation W21402883621 @default.
• W2140288362 hasLocation W21402883622 @default.
• W2140288362 hasLocation W21402883623 @default.
• W2140288362 hasOpenAccess W2140288362 @default.
• W2140288362 hasPrimaryLocation W21402883621 @default.

• next